Jennifer Beecham

Lymphatics, Longevity, and Lucidity: A New Paradigm for Treating Neurodegeneration.

Jennifer Beecham is Chief Operating Officer and a co-founder of Rho Bio, a Yale spinout focused on developing lymphatic medicines. She brings four years of experience as Senior Associate Director of the Blavatnik Fund at Yale Ventures. There she managed over 50 unique therapeutic and health technology projects guiding faculty discoveries through preclinical development toward startup launch. Before Yale, Jennifer spent eight years at Reata Pharmaceuticals, where she contributed to the development and commercialization of SKYCLARYS (omaveloxolone), the first FDA-approved treatment for Friedreich’s ataxia. She holds degrees in Bioengineering and Biochemistry from the University of Pennsylvania, where she also completed her Master’s in Bioengineering.